- Global Pharma News & Resources

Substance Use Disorder Treatment Market | Global Industry Growth Rate, Key Players, Expansion Plans and Recent Developments 2022-2032

The Global Substance Use Disorder Treatment Market is forecasted to be estimated at US$ 14 Mn by 2032, up from US$ 7 Mn in 2022, advancing at a CAGR of 5.4% during the forecast period.

Request a Sample Report @

A growing number of treatment centres, as well as mergers with private recovery institutions to help extend treatment access to a wider range of people, are expected to accelerate market growth. However, because patients in developing economies have limited income, the high cost of substance use disorder treatment therapy is likely to limit market size.

On the contrary, rising government initiatives and funding for chronic-ill effects of substance abuse are expected to increase the size of the substance use disorder treatment market during the forecast period.

The market for substance use disorder treatment is expected to grow as tobacco use increases in developing and underdeveloped countries, particularly in Pacific and East Asian countries. Furthermore, the implementation of strategic initiatives by several market participants is expected to drive market growth even further.

Favorable reimbursement policies and advancements in treatment due to the psychological effects of substance abuse are expected to boost market share. Furthermore, government investments in technology and telecommunications to improve healthcare infrastructure are expected to boost market growth.

Prevention programmes and increasing drug awareness crusades to provide information on the dangers of mixing drugs and the stigma associated with drug use in order to support treatment and recovery are expected to drive market share. These include increased treatment utilisation, increased government intervention, incentives to reduce substance abuse, and increased patient awareness.

Technological Advancements Bring the Treatment to New Horizons

Technological advancements accelerating the production of digital devices are likely to aid in the treatment of substance use disorders. As a result, the increasing penetration of digitization has a positive impact on market share.

The size of the market for substance use disorder treatment is expected to grow with government assistance. Furthermore, the ‘Confidentiality of Substance Use Disorder Patient Records Regulation’ ensures confidentiality for individuals receiving substance abuse treatment, which is expected to drive market growth.

Increased awareness about the dangerous consequences of alcohol abuse, as well as an increase in the number of rehabilitation facilities, are expected to propel the market. Furthermore, a wide range of alcohol addiction treatment options, such as counselling, group therapy, and medication, are expected to boost the substance use disorder treatment market.

Compounding drugs to meet the needs of each individual patient significantly boosts global market growth. Furthermore, the availability of experienced psychologists to conduct therapy and skilled professionals capable of drug compounding is expected to increase demand for substance use disorder treatment.

The impact of substance use disorder has been dramatically increased through various campaigns by non-profit organisations and governments via advertisements on television, newspapers, magazines, and so on. This is expected to increase market size.

Contact our Market Research Specialist@

Reluctance to Opt for Treatment to be a Key Market Impeder

Poor treatment compliance in some countries, as well as individuals’ reluctance to access treatment modalities, are likely to stymie market growth. Similarly, the market is expected to suffer as a result of the discontinuation of behavioural therapies, which leads to relapse and patients opting for outpatient care.

Extending clinical trial periods, as well as incomplete health treatment programmes, are expected to limit market share. Similarly, insufficient services for treating substance abuse pose a significant market challenge.

What are the Revenue Opportunities for the Substance Use Disorder Treatment Market?

The high prevalence of comorbid illnesses can be attributed to incorrect prescription drugs. As a result, rising non-medical prescription drug consumption and rising overdose deaths are expected to drive market growth in the coming years.

Because of the high proportion of e-cigarette users in urban areas, the market for substance use disorder treatment presents a lucrative opportunity. This is due to E-cigarette research that estimated several major health issues associated with tobacco use.

What is the Competitive Landscape of the Substance Use Disorder Treatment Market?

Key market participants are constantly educating themselves in order to gain a better understanding of the psychological issues that result from long-term substance abuse. They are developing improved treatment options through mergers and acquisitions, as well as increasing awareness through campaigns.

Request Report Customization @

Other market players of the substance use disorder treatment market:

  • Cipla Limited
  • Intas Biopharmaceuticals
  • Alkermes
  • Allergan plc
  • Alkermes plc.
  • Indivior plc
  • Noramco
  • Mallinckrodt plc
  • BioCorRx Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Dr. Reddy’s Laboratories
  • Purdue Pharma L.P.
  • Orexo AB

Some of the recent developments in the substance use disorder treatment market are

  • Indivior plc and Aelis Farma announced a strategic partnership and option-license agreement in June 2021 to address the serious consequences of cannabis use disorders (CUD), including cannabis-induced psychosis (CIP).
  • JB Chemicals & Pharmaceuticals Ltd. will launch NOSMOK prescription medicated nicotine lozenges in May 2021 as part of a 360 Tobacco Cessation initiative on ‘World No Tobacco Day’ to help reduce the desire to consume tobacco.
  • Sandoz announced the commercial launch of reSET for patients with Substance Use Disorder in November 2018. (SUD).
  • In May 2018, US WorldMeds LLC received FDA approval for Lucemyra (Iofexidine hydrochloride), the first non-opioid-based treatment for the management of opioid withdrawal symptoms in adults.

Key companies profiled

Teva Pharmaceutical Industries Ltd., Reckitt Benckiser Pharmaceuticals Inc., GlaxoSmithKline plc, Alkermes plc., Pfizer Inc., Cipla Limited, Intas Biopharmaceuticals, Alkermes, Allergan plc, Indivior plc, Noramco, Mallinckrodt plc, BioCorRx Inc., Glenmark Pharmaceuticals Ltd., Dr. Reddy’s Laboratories, Purdue Pharma L.P., Orexo AB, etc.

Buy Now Complete Research Report@

Key Segments Profiled in the Substance Use Disorder Treatment Market Survey

By Type:

  • Alcohol Abuse Treatment
  • Nicotine Abuse Treatment
  • Drug Abuse Treatment

By Treatment:

  • Detoxification
  • Counselling & Behavioural Therapy
  • Medication
  • Support Group

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.


Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries:
Browse All Reports:

Editor Details

Last Updated: 09-Nov-2022